Press Releases

ROCKVILLE, Md. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present a
Posted: November 12, 2019
Total revenue of $102.1 million , compared to $103.0 million in third quarter 2018 Net product sales of $100.0 million , compared to $100.2 million in third quarter 2018 Operating earnings of $39.7 million , compared to $37.5 million in third quarter 2018 NDA submission for SPN-812 expected in
Posted: November 5, 2019
ROCKVILLE, Md. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business
Posted: October 24, 2019
ROCKVILLE, Md. , Aug. 26, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present a Company
Posted: August 26, 2019
Total revenue of $104.7 million , a 5.2% increase over 2018 Net product sales of $102.4 million , a 5.5% increase over 2018 Operating earnings of $42.6 million , a 19.3% increase over 2018 Submission of New Drug Application for SPN-812 on track for the second half of 2019 Revising full year 2019
Posted: August 6, 2019
Displaying 1 - 10 of 18